Expression of Hypoxia-inducible Factor 1α Predicts Clinical Outcome after Preoperative Hyperthermo-chemoradiotherapy for Locally Advanced Rectal Cancer

DOI PDF Web Site PubMed 被引用文献3件 参考文献60件
  • SHIOYA Mariko
    Department of Radiation Oncology, Gunma University Graduate School of Medicine
  • TAKAHASHI Takeo
    Department of Radiation Oncology, Gunma University Graduate School of Medicine
  • ISHIKAWA Hitoshi
    Department of Radiation Oncology, Gunma University Graduate School of Medicine
  • SAKURAI Hideyuki
    Department of Radiation Oncology, Graduate School of Comprehensive Human Sciences, University of Tsukuba
  • EBARA Takeshi
    Department of Radiation Oncology, Gunma University Graduate School of Medicine
  • SUZUKI Yoshiyuki
    Department of Radiation Oncology, Gunma University Graduate School of Medicine
  • SAITOH Jun-ichi
    Department of Radiation Oncology, Gunma University Graduate School of Medicine
  • OHNO Tatsuya
    Department of Radiation Oncology, Gunma University Graduate School of Medicine
  • ASAO Takayuki
    Department of General Surgical Science, Gunma University Graduate School of Medicine
  • KUWANO Hiroyuki
    Department of General Surgical Science, Gunma University Graduate School of Medicine
  • NAKANO Takashi
    Department of Radiation Oncology, Gunma University Graduate School of Medicine

書誌事項

タイトル別名
  • Expression of Hypoxia-inducible Factor 1.ALPHA. Predicts Clinical Outcome after Preoperative Hyperthermo-chemoradiotherapy for Locally Advanced Rectal Cancer

この論文をさがす

抄録

Hypoxia-inducible factor 1α (HIF-1α) is an intrinsic marker of tumor hypoxia. It has been considered that hypoxic conditions reduce radiosensitivity, but the role of HIF-1α in patients treated with preoperative therapy for rectal cancer is still unclear. The aim of this study was to evaluate the predictive value of tumor response to preoperative hyperthermo-chemoradiotherapy (HCRT) and the prognostic significance of HIF-1α expression in patients with locally advanced rectal cancer. Between 2003 and 2006, 50 patients with histologically proven rectal adenocarcinoma who underwent HCRT followed by surgery were investigated. HIF-1α expression was immunohistochemically evaluated using pre-treatment biopsies. The total radiation dose was 40–50 Gy and chemotherapy consisted of 5-FU and LV administered by continuous infusion on Day 1–5, Day 15–19, and Day 29–33 during radiotherapy. Hyperthermia treatment was performed for once a week for 2–5 sessions. The surgical operation was performed 8 weeks after HCRT and each resected specimen was graded by histological criteria of the Japanese Classification of Colorectal Carcinoma. The effects of HIF-1α on clinical outcomes were analyzed by univariate and multivariate analysis. Positive HIF-1α expression was recognized in 42.0% of samples (21/50). Resected specimens that showed pathological grades 1, 2, and 3 numbered 17, 24, and 9 cases, respectively. There were no significant differences between the HIF-1α-positive group and HIF-1α-negative group for pathological grading and pCR. Overall survival (OS) rate at 3 years in the HIF-1α-negative group was 85.2%, which was significantly better than the 60.6% in the HIF-1α-positive group. Recurrence-free survival (RFS) rate at 3 years in the HIF-1α-negative group was 82.8%, being significantly better than 47.6% in the HIF-1α-positive group. In addition, elevated HIF-1α expression was significantly correlated with recurrence-free survival and metastasis-free survival rate in multivariate analysis. HIF-1α expression might be predictive of recurrence-free survival and metastasis-free survival rate for rectal cancer patients treated with HCRT.

収録刊行物

被引用文献 (3)*注記

もっと見る

参考文献 (60)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ